IDORSIA LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.012 CHF | -0.98% |
|
+5.89% | -4.82% |
| May. 02 | Idorsia Boosts Consent Fee Offer to 2024 Convertible Bond | MT |
| Apr. 26 | Idorsia Gets EU Medicines Regulator's Positive Opinion for Resistant Hypertension Treatment | MT |
| Sales 2023 * | 126M 139M | Sales 2024 * | 226M 250M | Capitalization | 360M 397M |
|---|---|---|---|---|---|
| Net income 2023 * | -407M -450M | Net income 2024 * | -416M -459M | EV / Sales 2023 * | 11.4 x |
| Net Debt 2023 * | 1.08B 1.2B | Net Debt 2024 * | 1.12B 1.24B | EV / Sales 2024 * | 6.55 x |
| P/E ratio 2023 * |
-0.97
x | P/E ratio 2024 * |
-1.36
x | Employees | 650 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 58.69% |
More Fundamentals
* Assessed data
More news
Latest transcript on Idorsia Ltd
More recommendations
More press releases
| 1 day | -0.98% | ||
| 1 week | +5.89% | ||
| Current month | +11.16% | ||
| 1 month | -21.41% | ||
| 3 months | +38.66% | ||
| 6 months | -4.64% | ||
| Current year | -4.82% |
1 week
1.78
2.12
1 month
1.652.64
Current year
1.293.70
1 year
1.299.75
3 years
1.2927.08
5 years
1.2933.88
10 years
1.2933.88
| Managers | Title | Age | Since |
|---|---|---|---|
Jean-Paul Clozel
CEO | Chief Executive Officer | 69 | 17-05-31 |
André Muller
DFI | Director of Finance/CFO | 60 | 17-05-31 |
Martine Clozel
CTO | Chief Tech/Sci/R&D Officer | 68 | 17-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jörn Aldag
BRD | Director/Board Member | 65 | 20-05-12 |
Peter Kellogg
BRD | Director/Board Member | 67 | 21-05-11 |
Jean-Paul Clozel
CEO | Chief Executive Officer | 69 | 17-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 773 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 2.012 | -0.98% | 401,006 |
| 24-05-02 | 2.032 | +12.27% | 1,249,507 |
| 24-04-30 | 1.81 | -2.95% | 392,903 |
| 24-04-29 | 1.865 | -1.84% | 181,276 |
| 24-04-26 | 1.9 | +9.07% | 669,806 |
Delayed Quote Swiss Exchange, May 03, 2024 at 11:30 am EDT
More quotes
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Calendar
2024-05-05
- Shareholders Meeting
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
2.012
CHF
Average target price
1.724
CHF
Spread / Average Target
-14.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.82% | 398M | |
| -1.43% | 104B | |
| +8.96% | 105B | |
| +4.40% | 22.94B | |
| -12.15% | 22.34B | |
| -4.36% | 19.25B | |
| -39.98% | 17.08B | |
| -10.04% | 16.96B | |
| +6.79% | 14.16B | |
| +38.61% | 12.63B |
- Stock Market
- Equities
- IDIA Stock
